VIDEO: Recent developments in psoriasis treatment

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

It is an exciting time for the treatment of psoriasis. There's several new agents that came to market recently, and two of them are topical nonsteroidal agents. So it's roflumilast or Zoryve, and tapinarof or Vtama. These are great new additions that are nonsteroidal topical agents that can be used once a day for areas where people don't want to use steroids as much, such as the face or the genitalia or the inverse areas.

So those have been a great addition. There's also, as many people know, bimekizumab or Bimzelx just got approved, and that is an IL-17A and F inhibitor, which is novel in the sense that no agent inhibits IL-17F and A simultaneously. So it's more, basically more potent than the existing IL-17A inhibitors. And so we've been seeing increased efficacy, so that's a nice addition.

And then spesolimab or Spevigo, which is an IL-36 inhibitor, got approved for pustular psoriasis, which granted is quite rare, but for those patients who come to the ER with a pustular psoriasis flare, it's really excellent to have.

It's highly effective and safer than putting them on the historical agents, cyclosporine and infliximab, prednisone, et cetera. Deucravacitinib or Sotyktu is also a new oral agent for psoriasis that inhibits TYK2, which is one of the JAK proteins. And this is exciting to have another oral agent that's mildly immunosuppressive to offer patients that's more targeted than some of the other JAK inhibitors on the market. So those are the most important new agents, and psoriasis, as everyone knows, is a hot area for research, and so I'm confident there will be more agents that are similar in the near future.